Key result
Combined high CRP and ADMA linked to ~109% increased risk of metabolic syndrome.
Why the study?
The association of serum asymmetric dimethylarginine and C-reactive protein levels with the risk of developing metabolic syndrome in middle-aged men was unclear.
Are high serum levels of ADMA and CRP associated with an increased risk of developing metabolic syndrome in middle-aged men?
Cohort (n=848)
Are high serum levels of ADMA and CRP associated with an increased risk of developing metabolic syndrome in middle-aged men?
The combination of high serum CRP and ADMA levels reliably predicts the risk of developing metabolic syndrome in middle-aged men.
Answers are grounded in this paper and cite their sources.
May identify higher-risk middle-aged men; hypothesis-generating and requires prospective validation before clinical use.
We aimed to examine whether serum levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, and C-reactive protein (CRP) are associated with the risk of developing metabolic syndrome in middle-aged men. In this longitudinal study, serum ADMA and CRP levels were measured in Japanese men without metabolic syndrome, which was diagnosed according to the currently accepted unified criteria. The subjects were followed-up for a maximum of four years to determine new-onset metabolic syndrome. A Cox proportional hazards model with adjusting for potential confounders was applied to determine the hazard ratio (HR) for developing metabolic syndrome according to serum levels of ADMA and CRP, considered either alone or in combination. Of the 848 subjects (mean age, 43 ± 6 years), 100 subjects developed metabolic syndrome. High ADMA levels (≥ 0.45 μmol/L) alone did not show a significant HR for developing metabolic syndrome, while high CRP levels (≥ 0.3 mg/L) did (HR 1.75, 95% CI 1.12–2.74). The combination of high levels of both CRP and ADMA had a high HR (2.09, 95% CI 1.12–3.76) as compared to low levels of both markers. In contrast, the HR was not significant in the combination of high CRP and low ADMA levels, as well as low CRP and high ADMA levels. Serum CRP, but not ADMA, levels were associated with the risk of metabolic syndrome. Nevertheless, the risk of metabolic syndrome could be predicted more reliably by considering these two markers together rather than CRP alone.
No takes yet. Share an insight, caveat, or question.
Otsuka et al. (2014) conducted a cohort in metabolic syndrome (n=848). High serum levels of both CRP (≥ 0.3 mg/L) and ADMA (≥ 0.45 μmol/L) vs. Low levels of both markers was evaluated on new-onset metabolic syndrome (HR 2.09, 95% CI 1.12-3.76). The combination of high serum levels of C-reactive protein and asymmetric dimethylarginine was associated with an increased risk of developing metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: